These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31685562)

  • 1. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
    Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.
    Høgdall D; O'Rourke CJ; Dehlendorff C; Larsen OF; Jensen LH; Johansen AZ; Dang H; Factor VM; Grunnet M; Mau-Sørensen M; Oliveira DVNP; Linnemann D; Boisen MK; Wang XW; Johansen JS; Andersen JB
    Clin Cancer Res; 2020 Nov; 26(21):5655-5667. PubMed ID: 32933994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
    Schultz NA; Christensen IJ; Werner J; Giese N; Jensen BV; Larsen O; Bjerregaard JK; Pfeiffer P; Calatayud D; Nielsen SE; Yilmaz MK; Holländer NH; Wøjdemann M; Bojesen SE; Nielsen KR; Johansen JS
    PLoS One; 2013; 8(6):e67059. PubMed ID: 23840582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.
    Alkhateeb A; Zubritsky L; Kinsman B; Leitzel K; Campbell-Baird C; Ali SM; Connor J; Lipton A
    J Gastrointest Cancer; 2014 Jun; 45(2):161-7. PubMed ID: 24446242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40.
    Palmquist C; Dehlendorff C; Calatayud D; Hansen CP; Hasselby JP; Johansen JS
    Pancreas; 2020 Jan; 49(1):53-61. PubMed ID: 31856080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
    Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
    PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis.
    Fuksiewicz M; Kotowicz B; Rutkowski A; Achinger-Kawecka J; Wagrodzki M; Kowalska MM
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818765209. PubMed ID: 29642772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.
    Rasmussen LS; Yilmaz MK; Falkmer UG; Poulsen LØ; Bøgsted M; Christensen HS; Bojesen SE; Jensen BV; Chen IM; Johansen AZ; Hansen CP; Hasselby JP; Holländer N; Nielsen SE; Andersen F; Bjerregaard JK; Pfeiffer P; Johansen JS
    Eur J Cancer; 2021 Feb; 144():72-80. PubMed ID: 33341448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.
    Hermunen K; Soveri LM; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
    Acta Oncol; 2020 Dec; 59(12):1416-1423. PubMed ID: 32790589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined plasma C-reactive protein, interleukin 6 and YKL-40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer.
    Videmark AN; Christensen IJ; Feltoft CL; Villadsen M; Borg FH; Jørgensen BM; Bojesen SE; Kistorp C; Ugleholdt R; Johansen JS
    Cancer Med; 2023 Mar; 12(6):6675-6688. PubMed ID: 36440611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of YKL-40 Predicts Poor Prognosis in Patients Undergoing Curative Resection of Pancreatic Cancer.
    Chen HT; Zheng JM; Zhang YZ; Yang M; Wang YL; Man XH; Chen Y; Cai QC; Li ZS
    Pancreas; 2017 Mar; 46(3):323-334. PubMed ID: 28099248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
    Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
    Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of serum YKL-40 in patients with cervical cancer.
    Roslind A; Palle C; Johansen JS; Christensen IJ; Nielsen HJ; Mosgaard BJ
    Scand J Clin Lab Invest; 2020 Dec; 80(8):687-693. PubMed ID: 33186077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
    Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
    Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
    Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
    Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality.
    Johansen JS; Pedersen AN; Schroll M; Jørgensen T; Pedersen BK; Bruunsgaard H
    Clin Exp Immunol; 2008 Feb; 151(2):260-6. PubMed ID: 18070151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
    Harutyunyan M; Christiansen M; Johansen JS; Køber L; Torp-Petersen C; Kastrup J
    Immunobiology; 2012 Jun; 217(6):652-6. PubMed ID: 22209156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum levels of YKL 40 and CA125 as a prognostic indicators in patients with endometrial cancer.
    Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Wagrodzki M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():141-147. PubMed ID: 28624692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
    Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
    Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.